Chips Surge, Beazer Gets a Buyout Bid, and Defense Memory Runs

Chip stocks are running hot again, Beazer Homes just got a surprise takeover bid from Dream Finders, and the Cerebras AI chip IPO priced at nearly double its original range.

This newsletter has everything worth knowing before tomorrow opens.

Many investors overlook deductions that could help minimize capital gains tax, such as:

Each comes with IRS rules and reporting requirements.

That’s why consulting a fiduciary financial advisor is often recommended.

See Advisor Matches

A senior executive at a trading firm sold $1.5 million worth of stock near its 52-week high, while two insiders at a rare earths name unloaded another $2.0 million after a massive 219% one-year run.

If you’re not an Elite Trade Club Insider, you’re missing out on where leadership is locking in gains after the market already did the heavy lifting.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Chips are running the show again, with Intel, Nvidia, Micron, and Qualcomm all among the most actively traded names as the AI trade refuses to cool off.

Oil crept higher after Saudi Aramco's CEO warned the market could lose 100 million barrels per week if Hormuz stays closed, estimating the crisis has already pulled roughly one billion barrels from global supply.

Cerebras, the AI chipmaker making chips the size of dinner plates to take on Nvidia, bumped its IPO range to $150-$160 ahead of Thursday's debut, targeting the year's biggest new offering at up to $4.8 billion.

And existing home sales rose just 0.2% in April against a 3% estimate, which is the housing market's polite way of saying it still isn't doing great.

Blackstone Inc (NYSE: BX) just agreed to buy Skroutz, Greece's largest e-commerce platform, for roughly $747 million. Skroutz is the go-to online shopping destination for Greek consumers.

Think of it as the Amazon of Greece. The founders are staying on to run the business while Blackstone takes majority ownership.

The previous owner doubled its money on this investment. Blackstone believes the real growth has not even started yet.

Why Greece, Why Now

Greece's digital economy has been growing rapidly as more consumers shift spending online. Skroutz has built the dominant marketplace in a country where e-commerce adoption still has significant room to expand compared to Western Europe.

Blackstone does not buy businesses in small markets unless it sees a path to making them much bigger.

You look at a country with accelerating digital adoption and a platform that already owns the market, and the opportunity becomes obvious.

E-Commerce Joins the Blackstone Empire

Blackstone is known for real estate, private credit, and infrastructure. Buying a consumer e-commerce platform in Southern Europe is a departure from the usual playbook.

It signals that Blackstone sees value in digital platforms operating in markets where growth has lagged but is now catching up fast.

You hand the dominant e-commerce platform of a fast-growing digital economy to one of the most aggressive investment firms on earth, and standing still is not an option.

Blackstone bought this to grow it, and the pace of that growth is what makes this story worth following.

Eli Lilly (NYSE: LLY) just got a major boost after the FDA proposed removing the key ingredients of its key weight-loss and diabetes drugs from the compounding list.

This move could limit cheaper copycat versions from pharmacies.

Lilly has been fighting compounders for over a year. The FDA just handed it the most powerful weapon yet.

Compounders Were Eating Into Demand

When Lilly's drugs were in shortage, compounding facilities legally began producing copycat versions at a fraction of the price. Telehealth companies built entire businesses around selling them.

Patients flocked to the cheaper alternatives. Every compounded dose sold was a dose Lilly did not sell. That dynamic has been a thorn in Lilly's business since 2022.

You build the most successful drug category in pharmaceutical history, only to watch others profit from discount versions of the same ingredients.

That frustration is now turning into regulatory protection.

This Proposal Came From the FDA Itself

The proposal is not final yet. But the direction is unmistakable. Your understanding of the competitive landscape around Lilly's drugs shifts significantly once compounders lose their legal pathway entirely.

You remove the discount competitors from a market where demand already exceeds supply, leaving the company holding the patents as the only option. That is exactly where Lilly is headed.

Find Elon Musk's next big launch and grab yourself an early stake, before the mainstream catches on and it becomes impossible to make huge gains.

Tesla soared 20,000% over 15 years. xAI grew 250X in two years.

SpaceX has made early backers 2,000X their money since 2010.

Today, we're revealing Elon's NEXT big launch.

*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

General Motors (NYSE: GM) just made a significant move by cutting hundreds of salaried IT roles as part of a broader restructuring effort.

The layoffs are not isolated; they are tied to a larger internal shift in which GM is evaluating which skills it needs going forward and where it wants to focus resources.

The decision reflects more than short-term cost control. It shows a company actively reshaping itself instead of maintaining its existing structure.

A Workforce Reset Is Underway

GM is not just reducing headcount; it is redefining roles. While some positions are being eliminated, others are still being hired, especially in areas tied to future priorities.

You now have a company actively replacing parts of its workforce rather than simply shrinking it.

That kind of reset signals intent. It shows a shift toward different capabilities and a new internal structure.

Refocusing on What Matters

Automakers are moving into more complex areas that require different expertise. GM is aligning its workforce with those needs, even if that means making difficult short-term decisions.

A Bigger Direction Is Taking Shape

Moves like this tend to come in phases. Companies reassess, restructure, and then rebuild around new priorities that define their future. The direction is becoming more defined.

You get a company actively reshaping itself from the inside, signaling a transition to a different operating model built for what comes next.

Everspin Technologies [MRAM] $39.86 (+47.68%)

Everspin announced a $40 million U.S. defense subcontract on April 29, and the stock has now roughly tripled in under two weeks.

Today’s move is pure momentum riding that catalyst, amplified by Monday’s broader chip sector frenzy.

At a $1 billion market cap with a $40M contract worth 73% of 2025 annual revenue, the math is getting stretched. Buy the story, respect the retracement risk.

Beazer Homes [BZH] $25.16 (+34.40%)

Dream Finders Homes submitted a $25.75 per share all-cash acquisition proposal today, a premium Bloomberg reported before the open.

Beazer has had 18 months of soft earnings, so a buyer stepping in confirms the land bank has real value.

The offer isn’t done yet, but with a cash bid on the table, the floor under BZH is now a lot more solid.

Navitas Semiconductor [NVTS] $22.65 (+24.45%)

Navitas makes GaN and silicon carbide power chips for AI data centers and has been one of 2026’s most explosive momentum trades, up over 400% year to date.

Today, it’s riding the broader chip sector frenzy that’s lifting Intel, Nvidia, and Micron across the board.

Revenue inflection isn’t expected until 2027, so this name moves fast in both directions.

Certara [CERT] $5.13 (-18.70%)

Certara reported Q1 revenue flat year over year, missing estimates, while adjusted EPS of $0.09 missed the $0.11 consensus and operating income swung to a loss.

Services revenue fell 4%, and a completed divestiture muddied the near-term outlook. The stock is down 28% for the year, and the new CEO has not yet landed a recovery narrative that sticks.

Power Solutions International [PSIX] $62.45 (-17.73%)

Robbins Geller filed a securities class action against PSIX today, alleging the company overstated its data center gross margin guidance and misled investors for nearly a year.

The stock already fell hard from its $121 peak after the March guidance reset. Strong Buy-rated with good fundamentals, but today’s lawsuit puts an overhang on the thesis until there’s more clarity.

NeuroPace [NPCE] $15.67 (-14.60%)

NeuroPace reports Q1 results today, and the pre-earnings pressure suggests the market is anxious about whether the RNS System’s strong recent momentum can continue.

At a $543 million Strong Buy-rated market cap with the stock near its 52-week high, any stumble in guidance gets punished hard.

The epilepsy device category is real, but high expectations leave a thin margin for error.

After analyzing thousands of companies, our analysts pinpointed the 5 Stocks Set to Double based on accelerating performance, improving fundamentals, and strong technical signals.

This newly released report explains why these five could be positioned for major moves in the year ahead.

While results aren’t guaranteed, previous reports uncovered gains as high as +175%, +498%, and +673%.

Access the free report before midnight.

See the 5 Stocks Set to Double

*Results may not represent all stock picks and may reflect partially closed positions. Investing involves risk, and past performance does not guarantee future results. This is not financial advice.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.